Presented with: CSHP Ontario Branch

Session sponsored by: Marcan

Learning objectives

• By the end of this session, participants will be able to:
  • Critically appraise current evidence on the safety and efficacy of direct oral anticoagulants (DOACs) in patients with chronic kidney disease (CKD). 
  • Compare and contrast the pharmacology and pharmacokinetic profiles of available DOACs, with emphasis on kidney clearance, dosing considerations, and implications for CKD management. 
  • Identify key knowledge gaps and uncertainties in the evidence guiding DOAC use across the spectrum of CKD, highlighting areas for clinical decision making and future research.

About Marisa Battistella

• Marisa trained at the University of Toronto, completed her residency at Sunnybrook Health Sciences Centre, and earned her PharmD from Idaho State University. She is a Professor, Affiliated Scientist at the Leslie Dan Faculty of Pharmacy and a Clinician Scientist at the University Health Network, where she practices in the hemodialysis unit. Her research in pharmaco-nephrology focuses on optimizing medication use in patients with chronic kidney disease, and she has published and presented widely in this area.